Royce & Associates LP Boosts Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Posted by admin on Aug 6th, 2022

Royce & Associates LP increased its stake in shares of Cryoport, Inc. (NASDAQ:CYRX – Get Rating) by 40.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,198 shares of the consumer goods maker’s stock after buying an additional 14,000 shares during the period. Royce & Associates LP owned about 0.10% of Cryoport worth $1,683,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in CYRX. Pinebridge Investments L.P. bought a new position in Cryoport during the fourth quarter worth about $77,000. Commonwealth Equity Services LLC bought a new position in Cryoport during the fourth quarter worth about $244,000. GSA Capital Partners LLP bought a new position in Cryoport during the fourth quarter worth about $247,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Cryoport by 49.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,937 shares of the consumer goods maker’s stock worth $351,000 after purchasing an additional 1,959 shares during the period. Finally, Ensign Peak Advisors Inc bought a new position in Cryoport during the fourth quarter worth about $355,000.

Cryoport Stock Up 6.7 %

CYRX stock opened at $39.40 on Friday. Cryoport, Inc. has a one year low of $19.82 and a one year high of $86.30. The company’s 50 day moving average price is $31.25 and its two-hundred day moving average price is $31.44. The company has a debt-to-equity ratio of 0.68, a current ratio of 14.98 and a quick ratio of 14.48.

Cryoport (NASDAQ:CYRX – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The consumer goods maker reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). The business had revenue of $64.20 million for the quarter, compared to analysts’ expectations of $64.58 million. Cryoport had a negative return on equity of 14.04% and a negative net margin of 125.96%. The company’s revenue was up 14.2% compared to the same quarter last year. During the same period last year, the business posted ($0.16) earnings per share. Equities research analysts forecast that Cryoport, Inc. will post -0.69 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. B. Riley cut their target price on shares of Cryoport from $61.00 to $55.00 in a research report on Tuesday, May 17th. KeyCorp cut their price objective on shares of Cryoport from $92.00 to $52.00 in a research report on Friday, May 6th. Needham & Company LLC raised their price objective on shares of Cryoport from $41.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, July 12th. BTIG Research dropped their target price on shares of Cryoport from $95.00 to $60.00 in a research report on Friday, May 6th. Finally, Roth Capital dropped their target price on shares of Cryoport from $90.00 to $67.00 in a research report on Tuesday, May 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $61.33.

Cryoport Company Profile

(Get Rating)

Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.